CLINICAL TRIALS PROFILE FOR FLUOROESTRADIOL F-18

All Clinical Trials for fluoroestradiol f-18

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01153672 ↗	Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy	Completed	National Cancer Institute (NCI)	N/A	2010-11-01	This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug
NCT01153672 ↗	Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy	Completed	University of Washington	N/A	2010-11-01	This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug
NCT01627704 ↗	Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer	Completed	Assistance Publique - Hôpitaux de Paris	N/A	2012-06-01	Compare the response rate after 6 months of hormone treatment (or a major change in hormone treatment) in metastatic breast cancer, according to the uptake of FES in metastatic lesions taking-up FDG on PET/CT at baseline. Hypothesis: best response rate will be observed in patients with all metastases taking up FES prior to treatment.
NCT01714128 ↗	FES-PET for Patients Treated on NCI Protocol 8762	Withdrawn	Washington University School of Medicine	N/A	2013-06-01	A significant number of all invasive breast cancers are hormone sensitive and may be candidates for treatment with hormonal therapy. This project will assess the ability and usefulness of imaging hormone-receptor status in breast cancer with positron emission tomography (PET) and 6α-[18F]fluoro-17β-estradiol (FES), an estrogen analogue in patients who are scheduled to be treated with hormonal therapy given in combination with a selective allosteric inhibitor of AKT protein kinase (MK2206) .
NCT01720602 ↗	Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy	Completed	National Cancer Institute (NCI)	N/A	2012-11-01	This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.

Clinical Trial Conditions for fluoroestradiol f-18

Condition Name

Condition Name for fluoroestradiol f-18
Intervention	Trials
Breast Cancer	5
Stage IV Breast Cancer	4
Metastatic Breast Cancer	4
Estrogen Receptor Positive	3

Condition MeSH

Condition MeSH for fluoroestradiol f-18
Intervention	Trials
Breast Neoplasms	18
Breast Neoplasms, Male	2
Pulmonary Arterial Hypertension	1
Ovarian Neoplasms	1

Clinical Trial Locations for fluoroestradiol f-18

Trials by Country

Trials by Country for fluoroestradiol f-18
Location	Trials
United States	34
France	3
China	3
Canada	2
Poland	1

Trials by US State

Trials by US State for fluoroestradiol f-18
Location	Trials
Washington	6
Pennsylvania	4
Utah	3
Texas	3
New York	3

Clinical Trial Progress for fluoroestradiol f-18

Clinical Trial Phase

Clinical Trial Phase for fluoroestradiol f-18
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	6

Clinical Trial Status

Clinical Trial Status for fluoroestradiol f-18
Clinical Trial Phase	Trials
Recruiting	11
Completed	6
Terminated	3

Clinical Trial Sponsors for fluoroestradiol f-18

Sponsor Name

Sponsor Name for fluoroestradiol f-18
Sponsor	Trials
National Cancer Institute (NCI)	5
University of Washington	4
University of Utah	2

Sponsor Type

Sponsor Type for fluoroestradiol f-18
Sponsor	Trials
Other	24
NIH	5
Industry	5